FDA Inspection 1100241 — Celgene Corporation
The FDA completed an inspection of Celgene Corporation on July 26, 2019 in Summit, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- July 26, 2019
- Fiscal Year
- 2019
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Summit, NJ (United States)
Additional Details
Sponsor, Contract Research Organization